{"id":"ezogabine-retigabine-ir","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Dizziness"},{"rate":"20-25","effect":"Somnolence"},{"rate":"10-15","effect":"Confusion"},{"rate":"10-15","effect":"Vertigo"},{"rate":"8-12","effect":"Tremor"},{"rate":"8-10","effect":"Blurred vision"},{"rate":"5-8","effect":"Urinary retention"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL41355","moleculeType":"Small molecule","molecularWeight":"303.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ezogabine is a potassium channel opener that stabilizes the open state of voltage-gated potassium channels (particularly Kv7 channels), allowing potassium efflux and hyperpolarization of neuronal membranes. This reduces neuronal firing and propagation of seizure activity. It is the first-in-class Kv7 channel opener approved for epilepsy.","oneSentence":"Ezogabine opens voltage-gated potassium channels in neurons, reducing neuronal excitability and seizure activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:39:29.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy in adults)"}]},"trialDetails":[{"nctId":"NCT01721317","phase":"PHASE4","title":"Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-12-19","conditions":"Seizures","enrollment":6},{"nctId":"NCT01336621","phase":"PHASE3","title":"Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-21","conditions":"Epilepsy","enrollment":98},{"nctId":"NCT01777139","phase":"PHASE3","title":"A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-11","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT01648101","phase":"PHASE3","title":"Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2012-08-29","conditions":"Epilepsy","enrollment":76},{"nctId":"NCT01332513","phase":"PHASE1","title":"An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-10","conditions":"Epilepsy","enrollment":36},{"nctId":"NCT01227902","phase":"PHASE3","title":"Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07","conditions":"Epilepsy","enrollment":203}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ezogabine/Retigabine IR","genericName":"Ezogabine/Retigabine IR","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ezogabine opens voltage-gated potassium channels in neurons, reducing neuronal excitability and seizure activity. Used for Partial-onset seizures (adjunctive therapy in adults).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}